If a cagrilintide dose is missed by five days, does the ladder reset?

Details up front: cagrilintide · five days.

I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.

Assume no laboratory access beyond what I can pay a third party for.

So: what is the actual procedure, and which steps matter as opposed to being ritual?

For a compound with a seven-day half-life, dose timing is much less consequential than people expect and dose rate is much more consequential.

Holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.

Missing a dose by three days on a weekly schedule takes the trough down by less than a factor of 1.35, which is well inside the variation you would see between two on-time weeks. Missing it by five or more days is where the label instructions start to differ between agents, and the reason is how close the next scheduled dose is rather than any mechanistic threshold.

The label instructions for a missed weekly dose differ between agents, and reading the actual prescribing information rather than a summary is worth the ten minutes — the thresholds are specific and the reasoning behind them is stated.

Worth noting that inter-individual variability in exposure at a given dose is substantial, which is why the ladder exists rather than a single population dose.

Write down in advance what would make you hold a step, because deciding that in the middle of a bad week is not when you are at your most analytical.

What the label says and what the trial protocols permitted are different documents, and the difference is instructive: protocols generally allowed a step to be delayed or reversed for intolerance, and a substantial minority of participants used that provision.

The argument against splitting a weekly dose is arithmetic rather than ideological. Peak-to-trough ratio for a seven-day half-life compound dosed weekly is about two. Split it into twice-weekly and the ratio falls to roughly 1.4. That is a real reduction in fluctuation and a negligible one in absolute terms, and you have doubled the number of stopper piercings and the number of small-volume measurements, each of which carries its own error.

To be exact about it, where the label ladders differ between agents, the differences track the potency ratio and the tolerability profile rather than anything deeper. It is worth reading the ladders side by side once, because the pattern — small starting dose, four-week steps, a defined maintenance range and a defined maximum — is identical in structure across the class.

SURMOUNT-4 is the withdrawal trial to read on the maintenance question: after an open-label lead-in, randomised withdrawal produced substantial regain in the placebo arm while continued treatment produced continued loss. It is the cleanest available answer to "what happens if I stop".

I would add that tolerability is not a proxy for benefit. Tolerating a higher dose easily is not evidence that you need one.

The short version: four-week steps because that is steady state, and the ladder is about the side effects, not the result.

edited 19 Jan 2026 by Dr_Bram_Verhoeven — clarified the distinction between purity and content

The steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.

Steady state, worked: with a half-life of about seven days and weekly administration, the accumulation ratio is roughly 1/(1 − 0.5) = 2, and you get to within about 97 per cent of steady state after five half-lives, so around thirty-five days — five weeks — after any dose change. A four-week step interval therefore has you escalating at roughly 94 per cent of the previous dose’s steady state, which is close enough to be sensible and not so close as to be conservative.

The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.

Read the actual prescribing information for the agent in question. It is short, specific, and more reliable than any summary of it.

Concretely, the titration schedule is a tolerability instrument, not an efficacy one. Nothing in the ladder is there to make the compound work better; every step exists to make the gastrointestinal adverse-event curve survivable.

The maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.

The pharmacokinetics of the acylated agonists are well described: absorption from the subcutaneous depot is slow and rate-limiting, the elimination half-life is approximately one week, and steady state is reached in four to five weeks. Every dosing question in this section follows from those three facts.

The limitation of all trial-derived dosing reasoning is that trial populations were selected, monitored and supported in ways that do not resemble anyone reading this.

If you take one thing from this: dose rate drives tolerability, dose level drives exposure, and they are separate levers.